Hochmair M.JMorabito AHao DYang C.-TSoo R.ACHIH-HSIN YANGGucalp RHalmos BWang LGolembesky AMärten ACufer T.2020-05-262020-05-2620181479-6694https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056628463&doi=10.2217%2ffon-2018-0711&partnerID=40&md5=1e98b1b8b40f24d11039785a90daefc7https://scholars.lib.ntu.edu.tw/handle/123456789/494907Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ?10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT0337077. ? 2015 2018 Maximilian Hochmair.afatinib; NSCLC; osimertinib; sequential; T790M[SDGs]SDG3afatinib; epidermal growth factor receptor; osimertinib; afatinib; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; osimertinib; piperazine derivative; protein kinase inhibitor; adult; aged; Article; Asian; brain metastasis; cancer prognosis; drug withdrawal; female; gene mutation; human; major clinical study; male; non small cell lung cancer; observational study; overall survival; priority journal; retrospective study; treatment duration; clinical trial; drug resistance; feasibility study; genetics; lung tumor; middle aged; mortality; multicenter study; mutation; non small cell lung cancer; pathology; survival analysis; treatment outcome; very elderly; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcomejournal article10.2217/fon-2018-0711303366932-s2.0-85056628463